AU2004270726A1 - Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters - Google Patents
Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters Download PDFInfo
- Publication number
- AU2004270726A1 AU2004270726A1 AU2004270726A AU2004270726A AU2004270726A1 AU 2004270726 A1 AU2004270726 A1 AU 2004270726A1 AU 2004270726 A AU2004270726 A AU 2004270726A AU 2004270726 A AU2004270726 A AU 2004270726A AU 2004270726 A1 AU2004270726 A1 AU 2004270726A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- glyceride
- fatty acid
- acid
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 220
- 150000001875 compounds Chemical class 0.000 title claims description 131
- 235000002378 plant sterols Nutrition 0.000 title claims description 126
- 235000012000 cholesterol Nutrition 0.000 title claims description 99
- 238000000034 method Methods 0.000 title claims description 40
- 150000002148 esters Chemical class 0.000 title description 41
- 230000002708 enhancing effect Effects 0.000 title description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 127
- 239000000194 fatty acid Substances 0.000 claims description 127
- 229930195729 fatty acid Natural products 0.000 claims description 127
- 150000004665 fatty acids Chemical class 0.000 claims description 127
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 94
- 235000021355 Stearic acid Nutrition 0.000 claims description 79
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 79
- 239000008117 stearic acid Substances 0.000 claims description 79
- 241000196324 Embryophyta Species 0.000 claims description 42
- 239000003921 oil Substances 0.000 claims description 34
- 235000019198 oils Nutrition 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 26
- 239000003638 chemical reducing agent Substances 0.000 claims description 26
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 24
- 235000015278 beef Nutrition 0.000 claims description 20
- -1 di-glyceride Chemical compound 0.000 claims description 20
- 235000019197 fats Nutrition 0.000 claims description 18
- 239000003760 tallow Substances 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 239000007787 solid Substances 0.000 claims description 14
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 14
- 230000032050 esterification Effects 0.000 claims description 12
- 238000005886 esterification reaction Methods 0.000 claims description 12
- 230000037406 food intake Effects 0.000 claims description 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 12
- 125000005457 triglyceride group Chemical group 0.000 claims description 12
- 235000014121 butter Nutrition 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 150000003904 phospholipids Chemical group 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 244000144972 livestock Species 0.000 claims description 7
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 6
- 235000021314 Palmitic acid Nutrition 0.000 claims description 6
- 235000021004 dietary regimen Nutrition 0.000 claims description 6
- 235000020778 linoleic acid Nutrition 0.000 claims description 6
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 6
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims description 6
- 235000004936 Bromus mango Nutrition 0.000 claims description 5
- 235000004863 Fevillea cordifolia Nutrition 0.000 claims description 5
- 244000034902 Fevillea cordifolia Species 0.000 claims description 5
- 241000598860 Garcinia hanburyi Species 0.000 claims description 5
- 235000014826 Mangifera indica Nutrition 0.000 claims description 5
- 235000009184 Spondias indica Nutrition 0.000 claims description 5
- 244000141804 Theobroma grandiflorum Species 0.000 claims description 5
- 229940110456 cocoa butter Drugs 0.000 claims description 5
- 235000019868 cocoa butter Nutrition 0.000 claims description 5
- 229940117709 gamboge Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000002152 aqueous-organic solution Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 241001093152 Mangifera Species 0.000 claims 4
- 235000013305 food Nutrition 0.000 description 38
- 235000016709 nutrition Nutrition 0.000 description 22
- 230000001906 cholesterol absorption Effects 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 20
- 239000000126 substance Substances 0.000 description 16
- 239000003925 fat Substances 0.000 description 14
- 238000008214 LDL Cholesterol Methods 0.000 description 13
- 235000010469 Glycine max Nutrition 0.000 description 12
- 210000002249 digestive system Anatomy 0.000 description 12
- 244000068988 Glycine max Species 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000903 blocking effect Effects 0.000 description 10
- 230000035764 nutrition Effects 0.000 description 10
- 241000699800 Cricetinae Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000008158 vegetable oil Substances 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 229930182558 Sterol Natural products 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 235000003702 sterols Nutrition 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 230000000378 dietary effect Effects 0.000 description 6
- 208000019622 heart disease Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 235000012424 soybean oil Nutrition 0.000 description 5
- 239000003549 soybean oil Substances 0.000 description 5
- 150000003432 sterols Chemical class 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 239000003784 tall oil Substances 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000005984 hydrogenation reaction Methods 0.000 description 4
- 235000014593 oils and fats Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001131 Pulp (paper) Polymers 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 235000013310 margarine Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 240000002791 Brassica napus Species 0.000 description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000003529 anticholesteremic agent Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000015219 food category Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 229940068065 phytosterols Drugs 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 102100031416 Gastric triacylglycerol lipase Human genes 0.000 description 1
- 241001562081 Ikeda Species 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108010091264 gastric triacylglycerol lipase Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000009643 reducing diet Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50078403P | 2003-09-05 | 2003-09-05 | |
| US60/500,784 | 2003-09-05 | ||
| PCT/US2004/029187 WO2005023832A1 (en) | 2003-09-05 | 2004-09-03 | Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2004270726A1 true AU2004270726A1 (en) | 2005-03-17 |
Family
ID=34272993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004270726A Abandoned AU2004270726A1 (en) | 2003-09-05 | 2004-09-03 | Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20050085451A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1660516A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007504254A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20060083451A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004270726A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2537744A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005023832A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060127449A1 (en) * | 2003-01-28 | 2006-06-15 | Hargrove James L | Method and composition for lowering cholesterol |
| EP2214481B1 (en) | 2007-10-15 | 2019-05-01 | United Animal Health, Inc. | Method for increasing performance of offspring |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2025314A1 (en) * | 1989-10-12 | 1991-04-13 | Ronald J. Jandacek | Triglycerides containing saturated fatty acids having 20 to 24 carbon atoms useful in lowering blood cholesterol levels |
| US5502045A (en) * | 1991-05-03 | 1996-03-26 | Raision Tehtaat Oy Ab | Use of a stanol fatty acid ester for reducing serum cholesterol level |
| FI111513B (fi) * | 1998-05-06 | 2003-08-15 | Raisio Benecol Oy | Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi |
| US5892068A (en) * | 1998-08-25 | 1999-04-06 | Mcneil-Ppc, Inc. | Preparation of sterol and stanol-esters |
| EP1180545B2 (en) * | 1999-05-26 | 2018-05-09 | Adeka Corporation | Vegetable sterol-containing fat compositions and process for producing the same |
| ES2248082T3 (es) * | 1999-06-25 | 2006-03-16 | Cognis Ip Management Gmbh | Empleo de esteroles y esteres de esterol nanometricos. |
| ATE259160T1 (de) * | 1999-11-05 | 2004-02-15 | Raisio Benecol Oy | Essbare fettmischungen |
| EP1121928B1 (en) * | 2000-01-31 | 2008-01-23 | Härting S.A. | Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides |
| JP4911815B2 (ja) * | 2000-04-28 | 2012-04-04 | 株式会社Ａｄｅｋａ | 植物ステロール含有油脂組成物 |
| IL147942A0 (en) * | 2002-01-31 | 2002-08-14 | Enzymotec Ltd | Method of fractionation of phytosterol esters in oil and products obtained thereby |
| JP2003246746A (ja) * | 2002-02-25 | 2003-09-02 | Kurabo Ind Ltd | リパーゼ阻害剤およびリパーゼ阻害作用を有する加工食品 |
-
2004
- 2004-09-03 AU AU2004270726A patent/AU2004270726A1/en not_active Abandoned
- 2004-09-03 KR KR1020067004617A patent/KR20060083451A/ko not_active Withdrawn
- 2004-09-03 EP EP04783435A patent/EP1660516A1/en not_active Withdrawn
- 2004-09-03 CA CA002537744A patent/CA2537744A1/en not_active Abandoned
- 2004-09-03 US US10/934,346 patent/US20050085451A1/en not_active Abandoned
- 2004-09-03 JP JP2006525530A patent/JP2007504254A/ja active Pending
- 2004-09-03 WO PCT/US2004/029187 patent/WO2005023832A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005023832A1 (en) | 2005-03-17 |
| CA2537744A1 (en) | 2005-03-17 |
| KR20060083451A (ko) | 2006-07-20 |
| JP2007504254A (ja) | 2007-03-01 |
| EP1660516A1 (en) | 2006-05-31 |
| US20050085451A1 (en) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thompson et al. | History and development of plant sterol and stanol esters for cholesterol-lowering purposes | |
| Berger et al. | Plant sterols: factors affecting their efficacy and safety as functional food ingredients | |
| Wasan et al. | Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils | |
| US8221818B2 (en) | Composition with health and nutrition promoting characteristics, containing interestified lipids and phytosterol, and related methods | |
| US8507466B2 (en) | Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy | |
| US20070078115A1 (en) | Phytosterol and/or phytostanol derivatives | |
| US20010034338A1 (en) | Composition and method for reducing serum cholesterol levels | |
| US5965449A (en) | Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders | |
| CN1370180A (zh) | 植物甾醇或植物甾烷醇与抗坏血酸的偶联物及其在治疗或预防心血管疾病中的用途 | |
| US20010046548A1 (en) | Anticholesterolemic edible oil | |
| KR20170060180A (ko) | 포만감 유발 조성물 | |
| KR100959704B1 (ko) | 콜레스테롤 및 트리글리세리드의 감소에 사용하기 위한디아실글리세롤 및 피토스테롤 에스테르 강화 오일 | |
| Carr et al. | Cholesterol-lowering phytosterols: factors affecting their use and efficacy | |
| JP2002534445A (ja) | 血中コレステロール及び／又は血中トリグリセリドの低下方法 | |
| Hayes et al. | Free phytosterols effectively reduce plasma and liver cholesterol in gerbils fed cholesterol | |
| Cilla et al. | Development of functional beverages: The case of plant sterol-enriched milk-based fruit beverages | |
| Thurnham | Functional foods: cholesterol-lowering benefits of plant sterols | |
| US20050085451A1 (en) | Compound and method for enhancing the cholesterol lowering property of plant sterol and stanol esters | |
| JP7213510B1 (ja) | 胆汁酸ミセル吸着剤、胆汁酸吸着剤、胆汁酸ミセル開裂剤及び脂肪吸収抑制剤 | |
| CN101305754A (zh) | 一种调节血脂保健食用油及其制备方法 | |
| Lin et al. | Vegetable oil intake: The distinctive trilateral relationship of bile acid, gut microbiota and health | |
| He et al. | Application of phytosterols in management of plasma cholesterol | |
| US20110059930A1 (en) | Composition for the Regulation of the Human Immune System and the Prevention and Treatment of Diseases Thereof | |
| Ho et al. | Beneficial effects of plant sterols/stanols-containing milk powder on lipid metabolism in hamsters | |
| Kim et al. | Dietary structured lipids and phytosteryl esters: blood lipids and cardiovascular status in spontaneously hypertensive rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |